All Hytest SARS-CoV-2 nucleoprotein (NP) antibodies (Cat. #3CV4), including monoclonal antibodies (MAbs) C706, C524, C518, C715, and C527, target the N-terminal part of the nucleoprotein, specifically the region N47-A173. 

The BA.4 variant contains the following mutations and deletions in the NP: P13L, del31/33, P151S, R203K, G204R, and S413R (all information about SARS-CoV-2 NP mutations is from https://outbreak.info/situation-reports). 

Both the BA.2.86 (Pirola) and EG.5 (Eris) variants carry the following mutations in NP: P13L, del31/33, R203K, G204R, and S413R. Additionally, FLiRT group variants (KP.3, KP.3.3, KP.2, and KP.1.1), as well as similar new variants (LB.1, KS.1.1, and the XEC variant—a combination of KS.1.1 and KP.3.3), have mutations and deletions in NP, including: P13L, del31/33, R203K, G204R, Q229K, and S413R. Importantly, no additional mutations have been observed in the N47-A173 region. 

In conclusion, Hytest SARS-CoV-2 NP antibodies (Cat. #3CV4: MAbs C706, C524, C518, C715, and C527) should reliably detect the Pirola and Eris variants, FLiRT group variants (KP.3, KP.3.3, KP.2, and KP.1.1), as well as the similar new variants LB.1, KS.1.1, and XEC.